About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

WORCESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell therapies into potential cures for difficult-to-treat cancers, today announced that by decision dated November 8, 2024, the Nasdaq Hearings Panel granted the Company’s request for an extension to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Mark ...

Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - November 12, 2024) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's shares will begin trading on the Nasdaq Global Market ("Nasdaq") at the opening of the U.S. market today under the new ticker symbol "BHST". The Company's common shares will continue to trade on the Canadian Securities Exchange ...

SAN DIEGO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on November 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 99,500 shares of its common stock to eleven new non-executive employees under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the “2021 Inducement Plan”). The stock options were granted as inducements material ...

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- At the end of the settlement date of October 31, 2024, short interest in 3,083 Nasdaq Global MarketSM securities totaled 12,172,949,545 shares compared with 12,303,886,017 shares in 3,089 Global Market issues reported for the prior settlement date of October 15, 2024. The mid-October short interest represents 3.02 days compared with 3.26 days for the prior reporting period. Short interest in 1,664 securities on The Nasdaq Capital MarketSM totaled 2,128,624,815 sha ...

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 50 points on Monday.The Dow traded up 0.69% to 44,294.18 while the NASDAQ fell 0.36% to 19,217.22. The S&P 500 also fell, dropping, 0.04% to 5,993.15.Check This Out: Top 4 Health Care Stocks That May Plunge This QuarterLeading and Lagging SectorsFinancials shares surged by 1.5% on Monday.In trading on Monday, information technology shares fell by 1.4%.Top HeadlineShares of Monday.com Ltd MNDY fell around 16% on Mond ...

SEATTLE, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum market value of publicly held shares (“MVPHS”) requirement under Nasdaq Listing Rule 5550(a)(5) (the "Rule") for continued listing. On November 7 ...

First and only NMPA-approved treatment for patients with CIDP in China  Second VYVGART Hytrulo indication approved in China  November 11, 2024 – 7:30am ET  Amsterdam, the Netherlands— argenx SE (Euronext & Nasdaq: ARGX) and Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) approved the supplemental Biologics License Application (sBLA) for VYVGART Hytrulo 1,000mg (5.6ml)/vial [efgartigimod alfa injection (subcutaneous injection)] for the ...

Nvidia and Meta Platforms led the Nasdaq-100 higher over the last two years.The Nasdaq-100 tracks the performance of the 100 largest non-financial companies listed on the Nasdaq Stock Exchange. Component weighting is adjusted quarterly in March, June, and September, and the entire index is reconstituted annually in December.The Nasdaq-100 is heavily weighted toward the technology sector, a corner of the market where the rise of artificial intelligence (AI) has been particularly impactful. Indeed, Nvidia (NV ...

Core Viewpoint - The JP Morgan Nasdaq Equity Premium Income ETF (JEPQ) offers a combination of a 15% price increase over the past year and a 9.5% dividend yield, but it carries risks related to dividend volatility and limited upside potential [2][5][10] Group 1: ETF Overview - JEPQ is an actively managed ETF that invests in stocks from the Nasdaq-100 index, which consists of the 100 largest stocks on the Nasdaq exchange, primarily in the technology sector [3] - The ETF employs a covered call strategy to generate income, which can benefit from market volatility [4] Group 2: Performance Metrics - Over the past year, JEPQ's price rose by 15%, while the total return, including reinvested dividends, was 27% [5] - The current yield based on the latest dividend payment is 9.5% [5] Group 3: Dividend Characteristics - The monthly dividend has fluctuated between approximately $0.34 and $0.55 per share, indicating significant variability in income [7] - This variability means that the dividend yield may not be reliable for income investors seeking consistent cash flow [6][7] Group 4: Investment Risks - The ETF's reliance on a volatile index can lead to emotional challenges for conservative investors, especially those relying on it for retirement income [8] - Selling covered calls may limit the upside potential of the ETF, as rising investments can be called away, which has been observed in its performance relative to the Nasdaq-100 index [9] - The ETF has not yet established a long performance history, making it uncertain whether it can effectively manage downside risks while providing consistent income [10]